Last reviewed · How we verify

NCT03362528

Database and Calibration of a Non-invasive Glucose Monitoring Device

Completed NA Last updated 4 December 2019
What this trial tests

NA trial testing WM3.4NR in Diabetes in 12 participants. Completed in 28 January 2019.

Timeline
25 September 2017
Primary endpoint
28 January 2019
28 January 2019

Quick facts

Lead sponsorRSP Systems A/S
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment12
Start date25 September 2017
Primary completion28 January 2019
Estimated completion28 January 2019
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

RSP Systems A/S

Who can join

18 and older, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical study has been launched to collect spectral raman data paired with validated glucose reference values in private homes of subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of WM3.4NR

Trials testing the same drug.

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other RSP Systems A/S trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03362528.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing